Background: The World Health Organization recommends quinine plus clindamycin as first-line treatment of malaria in the first trimester of pregnancy and as a second-line treatment for uncomplicated falciparum malaria when artemisinin-based drug combinations are not available. The efficacy of quinine plus clindamycin was compared with that of artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in children below 5 years of age.
Methods: An open-label, phase 3, randomized trial was conducted in western Kenya. Children aged 6-59 months with uncomplicated falciparum malaria were randomly assigned (1:1) via a computer-generated randomization list to receive 3 days of twice a day treatment with either oral quinine (20 mg/kg/day) plus clindamycin (20 mg/kg/day) or artemether-lumefantrine (artemether 20 mg, lumefantrine 120 mg) as one (for those weighing 5-14 kg) or two (for those weighing 15-24 kg) tablets per dose. The primary outcome was a PCR-corrected rate of adequate clinical and parasitological response (ACPR) on day 28 in the per-protocol population.
Results: Of the 384 children enrolled, 182/192 (94.8%) receiving quinine plus clindamycin and 171/192 (89.1%) receiving artemether-lumefantrine completed the study. The PCR-corrected ACPR rate was 44.0% (80 children) in the quinine plus clindamycin group and 97.1% (166 children) in the artemether-lumefantrine group (treatment difference - 53.1%, 95% CI - 43.5% to - 62.7%). At 72 h after starting treatment, 50.3% (94 children) in the quinine plus clindamycin group were still parasitaemic compared with 0.5% (1 child) in the artemether-lumefantrine group. Three cases of severe malaria were recorded as serious adverse events in the quinine plus clindamycin group.
Conclusions: The study found no evidence to support the use of a 3-day low dose course of quinine plus clindamycin in the treatment of uncomplicated falciparum malaria in children under 5 years of age in Kenya, where artemether-lumefantrine is still effective.
Trial Registration: This trial is registered with the Pan-African Clinical Trials Registry, PACTR20129000419241.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8809037 | PMC |
| http://dx.doi.org/10.1186/s12936-022-04050-8 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Effect of protease inhibitors on the intraerythrocytic development of Babesia microti and Babesia duncani, the causative agents of human babesiosis.
J Eukaryot Microbiol
November 2024
Department of Biological Sciences, Purdue University Fort Wayne, Fort Wayne, Indiana, USA.
Human babesiosis is a malaria-like, tick-borne infectious disease with a global distribution. Babesiosis is caused by intraerythrocytic, apicomplexan parasites of the genus Babesia. In the United States, human babesiosis is caused by Babesia microti and Babesia duncani.
View Article and Find Full Text PDFAnti-babesial activity of a series of 6,7-dimethoxyquinazoline-2,4-diamines (DMQDAs).
Acta Trop
January 2024
National Research Center for Protozoan Diseases, Obihiro University of Agriculture and Veterinary Medicine, Obihiro, Hokkaido 080-8555, Japan. Electronic address:
Diminazene aceturate (DA), imidocarb dipropionate (ID), atovaquone (ATO), azithromycin (AZI), clindamycin, and quinine have been used to treat animal and human babesiosis for many years, despite their negative effects and rising indications of resistance. Thus, finding anti-babesial compounds that can either treat the infection or lower the dose of drugs given has been a primary objective. Quinazolines are one of the most important nitrogen heterocycles, with a wide range of pharmacological activities including analgesic, anti-inflammatory, sedative-hypnotic, anti-histaminic, anti-cancer, and anti-protozoan properties.
View Article and Find Full Text PDFArticle Synopsis
- - Babesiosis is a tick-borne disease that has seen a rise in cases worldwide, particularly in the northern USA, where it now averages 2,000 cases annually, mainly caused by the parasite Babesia microti.
- - In Europe, there have been 56 reported cases of babesiosis since 1957, mostly due to the cattle parasite Babesia divergens, with some infections from B. microti imported from North America.
- - Diagnosis involves identifying parasites in blood samples and using molecular methods, while treatment includes antibiotics and quinine; the increase in cases is linked to factors like climate change, outdoor activities, and improved awareness and detection methods.
Case report: First report on human infection by tick-borne in the Amazon region of Ecuador.
Front Public Health
August 2023
Escuela de Medicina, Universidad Internacional del Ecuador, Quito, Ecuador.
Babesiosis is a protozoan disease acquired by the bite of different species of ticks. More than 100 spp. infect wild and domestic animals worldwide, but only a few have been documented to infect humans.
View Article and Find Full Text PDFA qualitative study of health workers' perspectives on malaria case identification and management among pregnant women in Savelugu Municipality, Ghana.
PLOS Glob Public Health
May 2023
Department of Learning Health Sciences and OB/GYN, University of Michigan, Ann Arbor, MI, United States of America.
Despite successes in malaria control interventions over the past two decades, malaria remains a major public health concern. Over 125 million women live in endemic areas and experience adverse pregnancy outcomes due to malaria. Understanding health workers' perspectives on malaria identification and management is important to informing policy changes on the control and eradication of the disease.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!